Biotechnology - Canada

Filter

Current filters:

Canada

Popular Filters

151 to 175 of 2120 results

AVEO and Astellas finally terminate tivozanib collaboration

14-02-2014

US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

Actelion’s Opsumit approved by SwissMedic for PAH patients

Actelion’s Opsumit approved by SwissMedic for PAH patients

14-02-2014

Swiss biotech firm Actelion announced today that SwissMedic has approved Opsumit (macitentan) for pulmonary…

ActelionBiotechnologyCardio-vascularNorthern EuropeOpsumitRegulation

NicOx appoints financial partner to assess Duchenne Muscular Dystrophy treatment

14-02-2014

French biotechnology firm NicOx (Euronext Paris: COX) has granted an undisclosed financial partner an…

BiotechnologyFranceGeneticsLicensingnaproxcinodNicOx

Kissei collaborates with Alteogen on biosimilars

14-02-2014

Japanese drugmaker Kissei Pharmaceutical has entered into a business collaboration agreement with South…

BiosimilarsBiotechnologyKissei PharmaceuticalResearch

Another milestone for GenVec in hearing and balance collaboration

13-02-2014

US biotech firm GenVec says it has achieved the third milestone in its collaboration with Swiss drug…

BiotechnologyCGF166FinancialGenVecLicensingNeurologicalNovartis

Aurigene and Pierre Fabre announce licensing agreement for novel immunotherapy

Aurigene and Pierre Fabre announce licensing agreement for novel immunotherapy

13-02-2014

Privately-owned Pierre Fabre and Aurigene, a leading Indian biotech company, have entered into an agreement…

Aurigene DiscoveryBiotechnologyFranceIndiaLicensingOncologyPierre Fabre

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

13-02-2014

Exelixis (NASDAQ: EXEL) have announced the appointment of Jeffrey Hessekiel as executive vice president…

BiotechnologyBoardroomExelixisOncologyUSA

Health Canada approves Celgene’s Pomalyst for multiple myeloma

Health Canada approves Celgene’s Pomalyst for multiple myeloma

12-02-2014

Regulatory agency Health Canada has approved US biotech firm Celgene’s drug Pomalyst (pomalidomide…

BiotechnologyCanadaCelgeneNorth AmericaOncologyPomalystRegulation

Creation of ABIVAX - a leader in therapeutic vaccines - in a Cuban collaboration

12-02-2014

French venture capital firm Truffle Capital has announced the creation of Paris-based ABIVAX in collaboration…

ABIVAXAnti-viralsBiotechnologyResearchVaccines

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Nanobiotix outlines development plan for NBTXR3 in soft tissue sarcoma

11-02-2014

Nanobiotix, a French nanomedicine company focused on cancer therapy, has announced today its development…

BiotechnologyNanobiotixNBTXR3OncologyResearch

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

11-02-2014

US biotech major Gilead Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration…

Antibiotics and Infectious diseasesBiotechnologyGilead SciencesledipasvirRegulationsofosbuvirUSA

Alchemia announces appointment of Santo Costa as chairman

Alchemia announces appointment of Santo Costa as chairman

11-02-2014

Australia-based biotech company Alchemia has announced the appointment of Santo Costa as non-executive…

AlchemiaAustraliaBiotechnologyBoardroom

Actelion 2013 sales and earnings beat expectations

Actelion 2013 sales and earnings beat expectations

11-02-2014

Switzerland-based Actelion, Europe’s largest biotech firm, has reported financial results for full-year…

ActelionBiotechnologyFinancial

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Survey: Pharma CEOs on the importance of technology, demographics and innovation

Survey: Pharma CEOs on the importance of technology, demographics and innovation

07-02-2014

A global survey of chief executives has revealed the priorities and concerns of pharmaceutical and life…

BiotechnologyBoardroomGlobalMarkets & MarketingPharmaceutical

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

07-02-2014

US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

Actelion gains approval in Australia for Opsumit in PAH

Actelion gains approval in Australia for Opsumit in PAH

07-02-2014

Swiss biotech firm Actelion (SIX: ATLN) has received approval of Opsumit (macitentan) for the treatment…

ActelionAustraliaBiotechnologyCardio-vascularOpsumitRegulation

Whistleblower law suit against Celgene unsealed

Whistleblower law suit against Celgene unsealed

07-02-2014

A US federal court yesterday unsealed a whistleblower/false claims law suit brought against US biotech…

BiotechnologyCelgeneLegalMarkets & MarketingNorth AmericaOncologyRevlimidThalomidUSA

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

All eyes on Sovaldi as Gilead reports financials, which were well above forecasts

All eyes on Sovaldi as Gilead reports financials, which were well above forecasts

05-02-2014

US antivirals-focused biotech firm Gilead Sciences posted financial results for the fourth quarter and…

BiotechnologyFinancialGilead SciencesSovaldi

151 to 175 of 2120 results

Back to top